Patient-derived colorectal cancer organoids were generated and cultured as described earlier [21 (link), 22 (link)]. In brief, the tissue was cut into small pieces and dissociated at 37 °C. Dissociated cells were passed through a 30 and 100 μm cell strainer and collected in advanced DMEM/F12 medium (Thermo Fisher Scientific GmbH, Waltham, Massachusetts, US) supplemented with Glutamax (Thermo Fisher Scientific GmbH, Waltham, Massachusetts, US), penicillin/streptomycin, HEPES, N-acetylcysteine (Merck Chemicals GmbH, Darmstadt, Germany), N-2 supplement (Thermo Fisher Scientific GmbH, Waltham, Massachusetts, US), B-27 supplement (Thermo Fisher Scientific GmbH, Waltham, Massachusetts, US), EGF (PeproTech GmbH, Hamburg, Germany), Y27632 (Absource Diagnostics GmbH, Munich, Germany), and amphotericin (Sigma-Aldrich Chemical, St. Louis, Missouri, US) and embedded in matrigel (Corning B.V., Amsterdam, Netherlands). For subcultivation, organoids were removed from matrigel and dissociated into small organoids using TrypLE (Thermo Fisher Scientific GmbH, Waltham, Massachusetts, US) and then transferred into fresh matrigel. For coculture experiments, organoids were dissociated into small organoids and 2,500–5,000 small organoids were seeded onto the peritoneum.
Free full text: Click here